Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
Faye CoeVivek MisraYamini McCabeHelen AdderleyLaura WoodhouseZaheen AyubXin WangSacha HowellMaria EkholmPublished in: Breast cancer research and treatment (2021)
Our results indicate that the ADPT lines is an important factor when predicting the outcome with eribulin chemotherapy in a palliative setting and that quantitative guidance on the likely PFS and OS with treatment can be provided using ADPT. Validation in additional cohorts is warranted.